Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

You said some are trying to downplay K efficacy, but when I mentioned stable diseases in some ovarian patients, you said tumors can stabilize on its own so it doesn't mean anything. So I guess it just happened that the tumors spread to stage 4 prior to K and stabilize on its own during K treatment.

One of the secondary endpoints is p21 and 67.5% of patients had an increase in p21 expression. Unless you say p53 can reactivate on its own, I think it's safe to say that K reactivates p53. That's efficacy and CTIX reported it.

http://cellceutix.com/cellceutix-announces-database-lock-in-phase-1-trial-of-kevetrin-a-promising-new-cancer-treatment-that-activates-p53/#sthash.fCll3RME.dpbs

Before a tumor can shrink, it has to stop growing first. Before a tumor can stop growing, p53 has to be reactivated first. K P1 confirmed the first step. With more frequent dosing in P2, hopefully tumors can start shrinking.